BC-1485
(BC1485) manufacturers
- BC-1485
-
- $293.00
-
2026-05-11
- CAS:2035085-19-7
- Purity: 98.86%
- Supply Ability: 10g
|
| | BC-1485
(BC1485) Basic information |
| Product Name: | BC-1485
(BC1485) | | Synonyms: | BC-1485
(BC1485);BC-1485;Benzamide, 4-[[(2,3-dihydro-2-oxo-1H-benzimidazol-5-yl)sulfonyl]amino]-N-[2-(dimethylamino)-1-methyl-2-oxoethyl]-;N-(1-(Dimethylamino)-1-oxopropan-2-yl)-4-((2-oxo-2,3-dihydro-1H-benzo[D]imidazole)-5-sulfonamido)benzamide | | CAS: | 2035085-19-7 | | MF: | C19H21N5O5S | | MW: | 431.47 | | EINECS: | | | Product Categories: | | | Mol File: | 2035085-19-7.mol |  |
| | BC-1485
(BC1485) Chemical Properties |
| density | 1.403±0.06 g/cm3(Predicted) | | pka | 8.32±0.20(Predicted) |
| | BC-1485
(BC1485) Usage And Synthesis |
| Description | BC-1485 is a first-in-class inhibitor of Fibrosis-inducing E3 ligase 1 (FIEL1 ), which disrupts FIEL1-directed PIAS4 ubiquitination. | | Uses | BC-1485 is a small molecule inhibitor of Fibrosis-inducing E3 ligase 1 (FIEL1). BC-1485 protects PIAS4 from ubiquitin-mediated degradation. BC-1485 decreases α-SMA, BAL and CXCL1. BC-1485 ameliorates fibrotic lung injury in murine models[1][2]. | | IC 50 | CXCR1 | | References | [1] Lear T, et al. Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4. J Exp Med. 2016 May 30;213(6):1029-46. DOI:10.1084/jem.20151229
[2] Lear T, et al. Therapeutic targets in fibrotic pathways. Cytokine. 2016 Dec;88:193-195. DOI:10.1016/j.cyto.2016.09.008 |
| | BC-1485
(BC1485) Preparation Products And Raw materials |
|